Chief Medical Officer · Coherus Oncology, Inc. (CHRS)

Barbara Finck

A named executive officer of Coherus Oncology in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,548,501

Salary $482,393Stock awards $0Bonus $7,955

FY2017: $1,148,913

3rd of 5 named executive officers at Coherus Oncology by FY2018 total.

5 named officers on file for Coherus Oncology, FY2018

Barbara Finck’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • CHRS’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Coherus Oncology’s whole pay program stands against its peers

  • Coherus Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CHRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2019 (DEF 14A).

Free

Get Barbara Finck’s full pay file as a PDF — free

More than this page: up to 10 years of Barbara’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Barbara Finck compensation by year

Coherus Oncology Summary Compensation Table · all 3 fiscal years held
In US dollars, as Coherus Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$429,364$469,844$482,393
Bonus$0$0$7,955
Stock awards$0$0$0
Option awards$883,147$572,100$843,596
Non-equity incentive$174,680$106,970$214,557
Pension and deferred compensation$0$0$0
All other$0$0$0
Total$1,487,192$1,148,913$1,548,501

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Coherus Oncology, Inc. DEF 14A filed April 10, 2019, accession 0001193125-19-102805, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Coherus Oncology, Inc. filed document, accession 0001193125-19-102805. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2019.

$1.5M
$1.1M
$1.5M
FY16
FY17
FY18
SalaryBonusNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option8,334—$29.00
Option27,793—$17.17
Option102,917—$10.05
Option33,500—$12.70

Per the Outstanding Equity Awards at Fiscal Year-End table in Coherus Oncology, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Coherus Oncology’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Dennis LanfearPresident, Chief Executive Office and Chairman of the Board of Directors$3,919,780
Vincent AnicettiChief Operating Officer$1,818,680
Barbara Finck · this pageChief Medical Officer$1,548,501
Jean-Frédéric ViretChief Financial Officer$1,478,211
Vladimir VexlerChief Scientific Officer$1,355,163

The full Coherus Oncology compensation record

free company brief

This page is one person within Coherus Oncology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Coherus Oncology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Coherus Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Barbara Finck's compensation dossier · One-time report. No refunds.